Search results
Is It Too Late to Buy Pfizer Stock?
The Motley Fool via AOL· 5 hours agoAre Pfizer's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its...
Former Pfizer Worker’s 401(k) Account Won’t Be Given to Ex-Wife
Bloomberg Law· 2 hours agoemployee can’t access his 401(k) account to satisfy a $75,000 judgment against him in a defamation lawsuit, a Pennsylvania federal judge said. Judge Juan R. Sánchez rejected her request with ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 23 hours agoPfizer disclosed on May 7 that a child participating in another...
Childress Capital Advisors LLC Has $583,000 Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 6 hours agoChildress Capital Advisors LLC boosted its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 2.2% during the 4th quarter, according to its most recent 13F filing with the Securities ...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 4 hours agoThis week, an FDA advisory committee unanimously recommended approval of Eli Lilly’s LLY Alzheimer's...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 1 day agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Fact Check: Joel Osteen Rumor Claims He's Leaving Ministry After Event Organizers Kicked Him Out of...
Snopes· 19 hours agoOn June 12, 2024, Snopes looked into a rumor claiming Joel Osteen — the leader of the Houston, Texas...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 2 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 22 hours agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 21 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...